Trial Profile
A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Utomilumab (Primary)
- Indications Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 18 Mar 2022 Results from NCT01307267, NCT02179918 and NCT02444793 comparing the anti drug antibody of utomilumab and its impact on the PK, safety, and efficacy in patients with advanced cancer, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 24 Apr 2018 Status changed from recruiting to discontinued due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.
- 27 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Oct 2017.